AI Article Synopsis

  • Three types of small RNA therapeutics—siRNAs, miRNAs, and ASOs—have advantages over traditional drugs by targeting gene products, offering new treatment avenues for various diseases.
  • While these small RNAs are valuable in preclinical research for gene silencing and drug target validation, off-target effects, particularly miRNA-like ones, can complicate results and lead to adverse effects.
  • The review discusses strategies such as sequence design and AI-based predictions to minimize these off-target effects, providing a comprehensive overview of current computational methods and experimental validation techniques to support small RNA therapy development.

Article Abstract

Three types of highly promising small RNA therapeutics, namely, small interfering RNAs (siRNAs), microRNAs (miRNAs) and the RNA subtype of antisense oligonucleotides (ASOs), offer advantages over small-molecule drugs. These small RNAs can target any gene product, opening up new avenues of effective and safe therapeutic approaches for a wide range of diseases. In preclinical research, synthetic small RNAs play an essential role in the investigation of physiological and pathological pathways as silencers of specific genes, facilitating discovery and validation of drug targets in different conditions. Off-target effects of small RNAs, however, could make it difficult to interpret experimental results in the preclinical phase and may contribute to adverse events of small RNA therapeutics. Out of the two major types of off-target effects we focused on the hybridization-dependent, especially on the miRNA-like off-target effects. Our main aim was to discuss several approaches, including sequence design, chemical modifications and target prediction, to reduce hybridization-dependent off-target effects that should be considered even at the early development phase of small RNA therapy. Because there is no standard way of predicting hybridization-dependent off-target effects, this review provides an overview of all major state-of-the-art computational methods and proposes new approaches, such as the possible inclusion of network theory and artificial intelligence (AI) in the prediction workflows. Case studies and a concise survey of experimental methods for validating in silico predictions are also presented. These methods could contribute to interpret experimental results, to minimize off-target effects and hopefully to avoid off-target-related adverse events of small RNA therapeutics. LINKED ARTICLES: This article is part of a themed issue Non-coding RNA Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.2/issuetoc.

Download full-text PDF

Source
http://dx.doi.org/10.1111/bph.17302DOI Listing

Publication Analysis

Top Keywords

off-target effects
28
small rnas
16
small rna
16
rna therapeutics
16
small
9
effects small
8
network theory
8
theory artificial
8
artificial intelligence
8
interpret experimental
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!